Baseline characteristics
| . | All (N = 413) . | Group I . | Group II . | Group III . | Group IV . | P value . |
|---|---|---|---|---|---|---|
| CNI-MTX (or MMF) (n = 210) . | ATG-CNI-MTX (n = 34) . | PTCy-ATG-CNI (n = 78) . | PTCy-CNI- MMF (n = 91) . | |||
| Age, median (IQR), y | ||||||
| Recipient | 56 (44-63) | 55 (45-62) | 58 (38-65) | 57 (47-63) | 56 (43-63) | .92 |
| Donor | 54 (44-61) | 53 (45-61) | 52 (33-60) | 55 (44-61) | 55 (42-62) | .20 |
| Patient sex, male, n (%) | 217 | 109 (51.9) | 21 (61.8) | 44 (56.4) | 43 (47.3) | .44 |
| Donor-recipient sex, n (%) | ||||||
| Male-male | 110 (26.6) | 62 (29.5) | 8 (23.5) | 17 (21.8) | 23 (25.3) | |
| Male-female | 94 (22.8) | 52 (24.8) | 4 (11.8) | 16 (20.5) | 22 (24.2) | .30 |
| Female-male | 107 (25.9) | 47 (22.4) | 13 (38.2) | 27 (34.6) | 20 (22) | |
| Female-female | 102 (24.7) | 49 (23.3) | 9 (26.5) | 18 (23.1) | 26 (28.6) | |
| Diagnosis, n (%) | ||||||
| Acute myeloid leukemia | 224 (54.2) | 116 (55.2) | 16 (47.1) | 44 (56.4) | 48 (52.7) | |
| Myelodysplastic syndrome | 63 (15.3) | 30 (14.3) | 5 (14.7) | 13 (16.7) | 15 (16.5) | |
| Myelofibrosis | 39 (9.4) | 22 (10.5) | 4 (11.8) | 10 (12.8) | 3 (3.3) | |
| Chronic myeloid leukemia | 19 (4.6) | 12 (5.7) | 1 (2.9) | 1 (1.3) | 5 (5.5) | |
| Chronic myelomonocytic leukemia | 11 (2.7) | 5 (2.4) | 1 (2.9) | 1 (1.3) | 4 (4.4) | .18 |
| Acute lymphoblastic leukemia | 48 (11.6) | 25 (11.9) | 6 (17.6) | 5 (6.4) | 12 (13.2) | |
| Others | 9 (2.2) | 0 (0.0) | 1 (2.9) | 4 (5.1) | 4 (4.4) | |
| Remission status at HSCT, n (%) | ||||||
| CR1 | 349 (84.5) | 182 (86.7) | 24 (70.6) | 68 (87.2) | 75 (82.4) | |
| CR >2 | 57 (13.8) | 28 (13.3) | 9 (26.5) | 7 (9.0) | 13 (14.3) | .06 |
| Active disease | 7 (1.7) | 0 (0.0) | 1 (2.9) | 3 (3.8) | 3 (3.3) | |
| DRI, n (%) | ||||||
| Low | 6 (1.5) | 3 (1.4) | 1 (2.9) | 0 | 2 (2.2) | |
| Intermediate | 203 (49.2) | 89 (42.4) | 19 (55.9) | 41 (52.6) | 54 (59.3) | .12 |
| High | 133 (32.2) | 81 (38.6) | 9 (26.5) | 25 (32.1) | 18 (19.8) | |
| Very high | 71 (17.2) | 37 (17.6) | 5 (14.7) | 12 (15.4) | 17 (18.7) | |
| Performance status, KPS <80, n (%) | 89 (21.5) | 50 (24.0) | 7 (20.6) | 17 (21.8) | 15 (16.5) | .54 |
| HCT-CI score ≥3, n (%) | 131 (31.7) | 71 (33.8) | 11 (32.4) | 21 (26.9) | 28 (30.8) | .58 |
| Conditioning intensity, n (%) | ||||||
| Reduced intensity | 215 (52%) | 82 (39.0) | 18 (52.9) | 72 (92.3) | 43 (47.3) | <.01 |
| Myeloablative | 198 (48%) | 128 (61.0) | 16 (47.1) | 6 (7.7) | 48 (52.7) | |
| TBI received, n (%) | 350 (84.5) | 206 (98.1) | 22 (64.7) | 75 (96.2) | 47 (51.6) | <.01 |
| ABO status, n (%) | ||||||
| Compatible | 259 (62.8) | 131 (62.4) | 18 (52.9) | 45 (57.7) | 65 (71.4) | |
| Bidirectional incompatibility | 23 | 11 (5.2) | 2 (5.9) | 3 (3.8) | 7 (7.7) | .12 |
| Major incompatibility | 71 | 33 (15.7) | 11 (32.4) | 17 (21.8) | 10 (11.0) | |
| Minor incompatibility | 60 | 35 (16.7) | 3 (8.8) | 13 (16.7) | 9 (9.9) | |
| CMV serostatus, n (%) | ||||||
| D+/R+ | 230 (55.7) | 125 (59.5) | 14 (41.2) | 39 (50.0) | 52 (57.1) | |
| D+/R− | 39 (9.4) | 22 (10.5) | 2 (5.9) | 8 (10.3) | 7 (7.7) | .97 |
| D−/R+ | 86 (20.8) | 34 (16.2) | 13 (38.2) | 19 (24.4) | 20 (22.0) | |
| D−/R− | 58 (14.1) | 29 (13.8) | 5 (14.7) | 12 (15.4) | 12 (13.2) | |
| Letermovir primary prophylaxis, n (%) | 15 (3.6) | 0 | 15 (3.6) | 0 | 0 | <.01 |
| Cryopreserved graft, n (%) | 201 (48.7) | 141 (67.1) | 7 (20.6) | 50 (64.1) | 3 (3.3) | <.01 |
| CD34+ cell dose median (IQR), ×106/kg | 6.8 (4.9-8.3) | 6.1 (4.4-8.5) | 6.8 (4.1-7.3) | 7.6 (5.4-10.7) | 7 (5.8-8) | .83 |
| . | All (N = 413) . | Group I . | Group II . | Group III . | Group IV . | P value . |
|---|---|---|---|---|---|---|
| CNI-MTX (or MMF) (n = 210) . | ATG-CNI-MTX (n = 34) . | PTCy-ATG-CNI (n = 78) . | PTCy-CNI- MMF (n = 91) . | |||
| Age, median (IQR), y | ||||||
| Recipient | 56 (44-63) | 55 (45-62) | 58 (38-65) | 57 (47-63) | 56 (43-63) | .92 |
| Donor | 54 (44-61) | 53 (45-61) | 52 (33-60) | 55 (44-61) | 55 (42-62) | .20 |
| Patient sex, male, n (%) | 217 | 109 (51.9) | 21 (61.8) | 44 (56.4) | 43 (47.3) | .44 |
| Donor-recipient sex, n (%) | ||||||
| Male-male | 110 (26.6) | 62 (29.5) | 8 (23.5) | 17 (21.8) | 23 (25.3) | |
| Male-female | 94 (22.8) | 52 (24.8) | 4 (11.8) | 16 (20.5) | 22 (24.2) | .30 |
| Female-male | 107 (25.9) | 47 (22.4) | 13 (38.2) | 27 (34.6) | 20 (22) | |
| Female-female | 102 (24.7) | 49 (23.3) | 9 (26.5) | 18 (23.1) | 26 (28.6) | |
| Diagnosis, n (%) | ||||||
| Acute myeloid leukemia | 224 (54.2) | 116 (55.2) | 16 (47.1) | 44 (56.4) | 48 (52.7) | |
| Myelodysplastic syndrome | 63 (15.3) | 30 (14.3) | 5 (14.7) | 13 (16.7) | 15 (16.5) | |
| Myelofibrosis | 39 (9.4) | 22 (10.5) | 4 (11.8) | 10 (12.8) | 3 (3.3) | |
| Chronic myeloid leukemia | 19 (4.6) | 12 (5.7) | 1 (2.9) | 1 (1.3) | 5 (5.5) | |
| Chronic myelomonocytic leukemia | 11 (2.7) | 5 (2.4) | 1 (2.9) | 1 (1.3) | 4 (4.4) | .18 |
| Acute lymphoblastic leukemia | 48 (11.6) | 25 (11.9) | 6 (17.6) | 5 (6.4) | 12 (13.2) | |
| Others | 9 (2.2) | 0 (0.0) | 1 (2.9) | 4 (5.1) | 4 (4.4) | |
| Remission status at HSCT, n (%) | ||||||
| CR1 | 349 (84.5) | 182 (86.7) | 24 (70.6) | 68 (87.2) | 75 (82.4) | |
| CR >2 | 57 (13.8) | 28 (13.3) | 9 (26.5) | 7 (9.0) | 13 (14.3) | .06 |
| Active disease | 7 (1.7) | 0 (0.0) | 1 (2.9) | 3 (3.8) | 3 (3.3) | |
| DRI, n (%) | ||||||
| Low | 6 (1.5) | 3 (1.4) | 1 (2.9) | 0 | 2 (2.2) | |
| Intermediate | 203 (49.2) | 89 (42.4) | 19 (55.9) | 41 (52.6) | 54 (59.3) | .12 |
| High | 133 (32.2) | 81 (38.6) | 9 (26.5) | 25 (32.1) | 18 (19.8) | |
| Very high | 71 (17.2) | 37 (17.6) | 5 (14.7) | 12 (15.4) | 17 (18.7) | |
| Performance status, KPS <80, n (%) | 89 (21.5) | 50 (24.0) | 7 (20.6) | 17 (21.8) | 15 (16.5) | .54 |
| HCT-CI score ≥3, n (%) | 131 (31.7) | 71 (33.8) | 11 (32.4) | 21 (26.9) | 28 (30.8) | .58 |
| Conditioning intensity, n (%) | ||||||
| Reduced intensity | 215 (52%) | 82 (39.0) | 18 (52.9) | 72 (92.3) | 43 (47.3) | <.01 |
| Myeloablative | 198 (48%) | 128 (61.0) | 16 (47.1) | 6 (7.7) | 48 (52.7) | |
| TBI received, n (%) | 350 (84.5) | 206 (98.1) | 22 (64.7) | 75 (96.2) | 47 (51.6) | <.01 |
| ABO status, n (%) | ||||||
| Compatible | 259 (62.8) | 131 (62.4) | 18 (52.9) | 45 (57.7) | 65 (71.4) | |
| Bidirectional incompatibility | 23 | 11 (5.2) | 2 (5.9) | 3 (3.8) | 7 (7.7) | .12 |
| Major incompatibility | 71 | 33 (15.7) | 11 (32.4) | 17 (21.8) | 10 (11.0) | |
| Minor incompatibility | 60 | 35 (16.7) | 3 (8.8) | 13 (16.7) | 9 (9.9) | |
| CMV serostatus, n (%) | ||||||
| D+/R+ | 230 (55.7) | 125 (59.5) | 14 (41.2) | 39 (50.0) | 52 (57.1) | |
| D+/R− | 39 (9.4) | 22 (10.5) | 2 (5.9) | 8 (10.3) | 7 (7.7) | .97 |
| D−/R+ | 86 (20.8) | 34 (16.2) | 13 (38.2) | 19 (24.4) | 20 (22.0) | |
| D−/R− | 58 (14.1) | 29 (13.8) | 5 (14.7) | 12 (15.4) | 12 (13.2) | |
| Letermovir primary prophylaxis, n (%) | 15 (3.6) | 0 | 15 (3.6) | 0 | 0 | <.01 |
| Cryopreserved graft, n (%) | 201 (48.7) | 141 (67.1) | 7 (20.6) | 50 (64.1) | 3 (3.3) | <.01 |
| CD34+ cell dose median (IQR), ×106/kg | 6.8 (4.9-8.3) | 6.1 (4.4-8.5) | 6.8 (4.1-7.3) | 7.6 (5.4-10.7) | 7 (5.8-8) | .83 |
ABO, blood group; CR1, first complete remission; D+, seropositive donor; D−, seronegative donor; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; R+, seropositive recipient; R−, seronegative recipient.